prikaz prve stranice dokumenta Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.
Pristup korisnicima matične ustanove
Znanstveni rad - Izvorni znanstveni rad
Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.
The European journal of health economics, 22 (2021), 1; 1. https://doi.org/10.1007/s10198-020-01262-0
Vrdoljak, Eduard; Sekerija, Mario; Pleština, Stjepko; Belac Lovasić, Ingrid; Katalinić Janković, Vera; Garattini, Livio; Bobinac, Ana; Vončina, Luka

Citirajte ovaj rad

Vrdoljak, E., Sekerija, M., Pleština, S., Belac Lovasić, I., Katalinić Janković, V., Garattini, L. ... Vončina, L. (2021). Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.. The European journal of health economics, 22. (1), 1. doi: 10.1007/s10198-020-01262-0

Vrdoljak, Eduard, et al. "Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.." The European journal of health economics, vol. 22, br. 1, 2021, str. 1. https://doi.org/10.1007/s10198-020-01262-0

Vrdoljak, Eduard, Mario Sekerija, Stjepko Pleština, Ingrid Belac Lovasić, Vera Katalinić Janković, Livio Garattini, Ana Bobinac i Luka Vončina. "Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.." The European journal of health economics 22, br. 1 (2021): 1. https://doi.org/10.1007/s10198-020-01262-0

Vrdoljak, E., et al. (2021) 'Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.', The European journal of health economics, 22(1), str. 1. doi: 10.1007/s10198-020-01262-0

Vrdoljak E, Sekerija M, Pleština S, Belac Lovasić I, Katalinić Janković V, Garattini L, i sur.. Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.. The European journal of health economics [Internet]. 2021. [pristupljeno 13.11.2024.];22(1):1. doi: 10.1007/s10198-020-01262-0

E. Vrdoljak, et al., "Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.", The European journal of health economics, vol. 22, br. 1, str. 1, 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:652428. [Citirano: 13.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:652428
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.
AutorEduard Vrdoljak
AutorMario Sekerija
AutorStjepko Pleština
AutorIngrid Belac Lovasić
AutorVera Katalinić Janković
AutorLivio Garattini
AutorAna Bobinac
AutorLuka Vončina
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za onkologiju i radioterapiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
This cost-effectiveness study analyses the expected impacts of activities proposed by the Croatian National Plan Against Cancer (NPAC) on cancer incidence and survival rates, as related to their respective costs. We evaluated the impact of the NPAC on two main outcomes, namely, reduced incidence and the improved survival of cancer patients, expressed as life years gained (LYGs), which enabled the calculation of incremental cost- effectiveness ratios (ICERs) in the form of cost per LYG. In the analysis of costs, we considered both the direct costs of NPAC activities as well as the wider indirect societal costs of cancer, thus permitting the calculation of the ICER both from the narrower national health insurer’s perspective (accounting only for the direct costs) and the wider societal perspective (accounting both for the direct and indirect costs). We estimated that on average, for all patients benefiting from the implementation of the NPAC in Croatia, an additional LYG would be yielded at the additional cost of €1.021 (societal perspective). The NPAC can, for some sites, even be considered a dominant intervention due to the negative cost/LYG ratio, meaning that it generates additional LYGs while at the same time, reducing total societal costs. Taking a narrower health insurer’s perspective (i.e., accounting only for the direct costs), the NPAC produces an additional LYG at an additional cost of €1.408. Both cost per LYG estimates can be considered cost-effective investment options.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaThe European journal of health economics
Brojčani podacivol. 22, br. 1, str. 1
p-ISSN1618-7598
DOIhttps://doi.org/10.1007/s10198-020-01262-0
URN:NBNurn:nbn:hr:184:652428
Datum objave publikacije2021
URL dokumentahttp://bib.irb.hr/1107054
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2023-02-07 09:26:46